Two‐Year Data of Tapered Dupilumab Shows High Effectiveness in Chronic Rhinosinusitis with Nasal Polyps With Nonsteroidal Anti‐inflammatory Drug‐Exacerbated Respiratory Disease
Allergy · 2025
DOI: 10.1111/all.16579 ↗Kurz gefasst
Fachartikel in der Zeitschrift Allergy, 2025. Verfasst von H B E Elzinga und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Nasal Polyps, Antibodies, Monoclonal, Humanized, Sinusitis, Rhinitis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Amsterdam UMC, AERO, GlaxoSmithKline foundation.
Abstract (Originalsprache)
Background
Patients with Non‐steroidal anti‐inflammatory drugs ( NSAID )‐Exacerbated Respiratory Disease (N‐ ERD ) can suffer from difficult‐to‐treat primary diffuse type 2 chronic rhinosinusitis with nasal polyps ( CRSwNP ). This study evaluates dupilumab effectiveness and dose tapering in CRSwNP patients with N‐ ERD compared to those without.
Methods
A real‐world prospective cohort with CRSwNP patients, with N‐ ERD or without ( CRSwNP ‐ NOS ; not otherwise specified), aged ≥ 18 treated with dupilumab 300 mg subcutaneously every 2 weeks. In case of clinical control, the interdose interval was prolonged every 6 months with steps of 2 weeks. (Clinical) data were collected at baseline, 24 weeks, and 2 years of treatment.
Results
Most baseline characteristics, including Nasal Polyp Score ( NPS ), Sino‐Nasal Outcome Test‐22 ( SNOT ‐22), and Sniffin′ sticks‐12 test ( SSIT ‐12) were comparable between groups (N‐ ERD n = 105, CRSwNP ‐ NOS n = 293). There was a higher prevalence (91.5% vs. 71.1%, p < 0.001) but comparable control of asthma in N‐ ERD patients (asthma control test [ ACT] : N‐ ERD 66.7% less controlled/uncontrolled vs. CRSwNP ‐ NOS 58.3%, p = 0.21). All outcomes improved significantly with dupilumab treatment at 24 weeks and remained improved after 2 years, without intergroup differences (median scores at 24 weeks for N‐ ERD patients vs. CRSwNP ‐ NOS , respectively: NPS : 2 vs. 1, p = 0.65; SNOT ‐22: 18 vs. 19, p = 0.27; SSIT ‐12: 7 vs. 8, p = 0.02; ACT : 21 vs. 22, p = 0.11). Dose tapering was possible in the majority of patients, with almost half at an 8–12 weeks interval in both groups after 2 years.
Conclusion
Dupilumab shows comparable effectiveness and taper feasibility between CRSwNP N‐ ERD patients and CRSwNP ‐ NOS patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Head and Neck Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
- Department of Otorhinolaryngology, Alrijne Hospital, Leiden, the Netherlands.
- Department of Otorhinolaryngology, Isala Hospital, Zwolle, the Netherlands.
ORCID-Profile: H B E Elzinga, J J Otten, W J Fokkens, S Reitsma
Förderung
- Amsterdam UMC
- AERO
- GlaxoSmithKline foundation
- Novartis
- Sanofi
- Amsterdam University Medical Centers
Zitieren
APA
Elzinga, H. B. E., Otten, J. J., Cornet, M. E., Rinia, A. B., Van Der Lans, R. J. L., Fokkens, W. J., Reitsma, S., & PolyREG Consortium (2025). Two‐Year Data of Tapered Dupilumab Shows High Effectiveness in Chronic Rhinosinusitis with Nasal Polyps With Nonsteroidal Anti‐inflammatory Drug‐Exacerbated Respiratory Disease. Allergy. https://doi.org/10.1111/all.16579
Vancouver
Elzinga HBE, Otten JJ, Cornet ME, Rinia AB, Van Der Lans RJL, Fokkens WJ, et al. Two‐Year Data of Tapered Dupilumab Shows High Effectiveness in Chronic Rhinosinusitis with Nasal Polyps With Nonsteroidal Anti‐inflammatory Drug‐Exacerbated Respiratory Disease. Allergy. 2025. doi:10.1111/all.16579
BibTeX
@article{Elzinga2025,
author = {Elzinga, H B E and Otten, J J and Cornet, M E and Rinia, A B and Van Der Lans, R J L and Fokkens, W J and Reitsma, S and PolyREG Consortium, PolyREG Consortium},
title = {Two‐Year Data of Tapered Dupilumab Shows High Effectiveness in Chronic Rhinosinusitis with Nasal Polyps With Nonsteroidal Anti‐inflammatory Drug‐Exacerbated Respiratory Disease},
journal = {Allergy},
year = {2025},
doi = {10.1111/all.16579}
}
EUVIMED